Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...
Morningstar6d
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member ...
Le Lézard6d
Hyundai ADM Demonstrates Anti-Metastatic Effect of 'PenetriumTM' in TNBC Preclinical Study
Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant anti-metastatic efficacy in a preclinical study ...
Center for Biosimilars18h
Biosimilars Gastroenterology Roundup: March 2025
As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, ...
pharmaphorum3d
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
With multiple entrants – including Stada’s Uzpruvo, Sandoz’s Pyzchiva, Celltrion’s Steqeyma, and Amgen’s Wezenla – clinicians may gravitate toward lower-cost alternatives, potentially ...